Combination of two drugs in tuberculosis treatment

Study on bio enhancer in the treatment of tuberculosis with Rifampicin : An evidence based update - A Randomized Controlled Tial

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

CTRI

Registry ID

CTRI/2015/01/005475

Enrollment

Registered

2015-01-29

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- New sputum positive patients

Interventions

Intervention1: Patients in intervention group will be treated with Risorine kit: (one Risorine capsule [Rifampicin 200mg + Isoniazid 300mg + Piperine 10mg] + one tablet of Ethambutol 800mg + two table

Eligibility

Inclusion criteria

Inclusion criteria: Patient who is willing to give informed consent and sputum positive patient

Exclusion criteria

Exclusion criteria: Pregnant and lactating women and Patient who is unwilling to participate in the trial

Design outcomes

Primary

Measure	Time frame
Sputum conversion rate, improvement in lung function, chest x rayTimepoint: one year	—

Secondary

Measure	Time frame
Improvement in QoL and cognitive functionTimepoint: 6 months	—

Countries

India

Contacts

Public ContactMG Rajanandh

Department of Pulmonary Medicine

devarajmail@yahoo.com09381206124

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026